PACB vs AQB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PACB Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pacific Biosciences of California, Inc. (PACB) driven by superior Momentum & Technical, Options & Structure while AQB counters with relative strength in Growth & Margin. Fundamentally, PACB trades at N/M Forward P/E with -333.0% operating margin (+5.5% YoY revenue) versus AQB at N/M Forward P/E and 0.0% operating margin (-93.5% YoY). In options structure, PACB sits in BREAKDOWN (97th %ile IV; Dealer Gamma Walls on Pro) against AQB sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PACB Revenue | AQB Revenue | PACB Op. Margin | AQB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $80M | $0M | -128.4% | -12264.6% | PACB |
| FY2019 | $90M | $0M | -110.6% | -7057.3% | PACB |
| FY2020 | $80M | $0M | -132.3% | -12727.1% | PACB |
| FY2021 | $130M | $0M | -161.2% | -1883.0% | PACB |
| FY2022 | $130M | $0M | -239.4% | -711.6% | PACB |
| FY2023 | $200M | $0M | -166.8% | -552.9% | PACB |
| FY2024 | $150M | N/A | -308.0% | N/A | PACB |
| FY2025 | $160M | N/A | -346.2% | N/A | PACB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PACB | AQB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $574.5M | $9.7M | Larger Scale | PACB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +5.5% | -93.5% | Higher Growth | PACB |
| Operating Margin (TTM) Profitability | -333.0% | 0.0% | Higher Margin | AQB |
| Net Profit Margin Profitability | -81.3% | 0.0% | Higher Margin | AQB |
| Return on Equity (ROE) Capital Efficiency | -929.3% | -68.9% | Higher ROE | AQB |
| 52-Week Range Position Momentum | 32% ($1โ$3) | 11% ($1โ$2) | Stronger Trend | PACB |
| Beta / 30D Volatility Risk Regime | 2.24ฮฒ ยท 109% Vol | 0.93ฮฒ ยท 117% Vol | Lower Realized Risk | PACB |
| Unified Institutional Score Composite Signal | 50.1 / 100 (HOLD) | 44.6 / 100 (HOLD) | Higher Composite | PACB |